Objective: To assess the potential benefit of the addition of a covered stent to a subintimal recanalized artery in patients with femoro-popliteal occlusions. Methods: From September 2003 to October 2005, we retrospectively analyzed all patients admitted for severe claudication or critical limb ischemia related to long femoro-popliteal occlusions and treated with subintimal recanalization. Patients were divided into two groups depending on whether they received a stent or not. All patients in the group treated with stent received a stent graft, and the entire length of the recanalized artery was covered in each case. Demographic data, indications, procedure, and outcomes were examined using survival analysis statistical techniques. Subintimal angioplasty (SA) was initially introduced to treat long chronic occlusions of the superficial femoral artery (SFA) 1 and was then extended to the tibial arteries.
Subintimal angioplasty (SA) was initially introduced to treat long chronic occlusions of the superficial femoral artery (SFA) 1 and was then extended to the tibial arteries. 2 Despite poor long-term patency, 2-5 the procedure has gained widespread acceptance owing to the good limb salvage rate 2, 6 and the minimally-invasive aspect of the procedure. The factors affecting patency after subintimal angioplasty are not well defined. Many reports 5, 7, 8 have studied these factors but none of them advocate stenting. Only three series [9] [10] [11] report routine use of stents after SA. The results are controversial and the benefit of the stent is not clear.
This technique is based on the creation of a new lumen, between the intima and the media, free from atheroma by using balloon angioplasty. In the procedure initially described by Bolia et al, 1 stents were used only in case of suboptimal angioplasty, defined as residual stenosis Ͼ30%. Our procedure differs from the initial procedure described by Bolia in that we stented the entire length of the recanalized artery.
This study was designed to assess whether the addition of a covered stent to a subintimal recanalized artery modifies the results in terms of patency and limb salvage, compared with the standard Bolia technique 12 in patients with long femoro-popliteal occlusions.
METHODS AND MATERIALS
We retrospectively reviewed all patients admitted to our department from September 2003 to October 2005 for severe claudication or critical limb ischemia (CLI) with long femoro-popliteal occlusions (n ϭ 346) and treated with subintimal angioplasty (n ϭ 53). During the same period, 174 patients underwent above or below-knee femoropopliteal bypass, eight patients with critical limb ischemia had primary amputation because of severe mental impairment (clinical dementia) and/or function impairment (elderly and non ambulatory patients), and 11 pa-tients with claudication were assigned to medical therapy alone with improvement of walking distance.
Patients were divided into two groups depending on whether they were treated only with SA (group 1) or with SA plus stenting (group 2). This cohort of patients represented 19.6% of the total number of patients treated during the same period in our unit for lower limb ischemia and 11% of those treated for claudication. During the study period, all patients with critical limb ischemia or disabling claudication were evaluated by clinical examination and duplex ultrasonography. They subsequently underwent either magnetic resonance angiography (MRA) or digital subtraction angiography (DSA) to assess the location and extent of the atherosclerotic disease. SA was limited to younger patients (active patients less than 50 years of age) with disabling claudication (less than 100 meters) and to either other patients with significant medical comorbidities or cases of autologous veins that were unavailable for bypass. The comorbid conditions included: recent myocardial infarction (Ͻ6 weeks), symptomatic coronary disease, renal insufficiency (creatinine level Ͼ 2 mg/dL or dialysis-dependant), or severe chronic obstructive pulmonary disease. 13 The decision to undertake stenting or not depended on the surgeon's preference, the extent of the femoro-popliteal occlusion above or below the knee, and the hemodynamic results on the perioperative angiogram. For practical purposes, stent graft was performed for all above-the-knee femoro-popliteal occlusions for some surgeons and, for the others, only in cases of blood flow limitation with dissection flaps or residual stenosis greater than 30% after above-theknee femoro-popliteal recanalization. In no case stent graft was used for below-the-knee occlusions. Combined procedures included all endovascular or surgical procedures utilized during the femoro-popliteal recanalization in order to improve inflow and/or outflow.
In patients with critical limb ischemia and severe stenosis or occlusion above and/or below the femoro-popliteal occlusion, we systematically performed the treatment of these lesions in conjunction with the femoro-popliteal recanalization. For claudicants, we corrected only the iliac or common femoral or profunda femoris artery stenosis as in inflow procedure. Infrapopliteal artery lesions were not treated in this group of patients.
The demographic data, associated comorbidities, indications, and occlusive lesions in each group are summarized in Table I . According to the extent of the occlusion into the femoro-popliteal segment and the site of reentry, we arbitrarily divided the lesion level into: (1) proximal, middle, or distal SFA, (2) total SFA occlusion, (3) femoro-popliteal, or (4) popliteal occlusion (Table II) .
All procedures were performed in an operating room under general anesthesia or local anesthesia with deep sedation. The ipsilateral common femoral artery was the preferred angiographic access. The controlateral femoral artery puncture was used in case of flush SFA occlusion. For patients with significant stenosis of common femoral artery or the profunda femoris artery, a surgical approach with a femoral bifurcation endarterectomy was first performed; thereafter, the patch graft used for the closure of the arteriotomy was punctured, and the endovascular procedure was achieved. An angiogram was made via a 5 Fr sheath mainly to plan for the reentry zone. A 5 Fr straight angiography catheter (Glidecath; Terumo Medical Corporation, Somerset, NJ) in combination with a soft angled 0.035 inch hydrophilic guide wire were commonly used to perform the subintimal dissection. Sometimes, especially in cases of very calcified artery or long occlusion, the progress of the guide wire in the subintimal space was very difficult; a 5 or 6 mm balloon catheter was used to dilate the subintimal channel and help the advancement of the guide wire loop. The reentry into the true lumen was performed either with catheter guide wire manipulations or with simple pushing of the looped guide wire at the end of the occlusion site. After confirmation of reentry, the whole subintimal space was dilated with 6 mm x 80 mm balloon angioplasty catheters (Wanda Balloon; SciMed, Boston Scientific, Natick, Mass) for SFA lesions inflated at 12 to 14 atmospheres for 60 seconds, whereas 4 to 5 x 40 mm balloon catheters (Wanda Balloon) were used for popliteal angioplasty. An angiogram was then performed to assess the results. When indicated, stents were deployed to cover the entire length of the recanalized artery. Five or 6 mm stent graft (Viabahn; W.L. Gore & Associates, Flagstaff, Ariz) was exclusively used in these patients. Technical success was defined as the creation of extraluminal dissection, reentry into the true lumen, and establishment of antegrade flow through the new lumen with Ͻ30% residual stenosis. Following a successful procedure, the patients in the non-stent group received aspirin and clopidogrel for 1 month, and those in the stent group received the same therapy for 6 months, followed by either aspirin or clopidogrel. All patients were monitored at 1, 6, and 12 months with a clinical examination and duplex scan. At each office visit, all patients were checked through the anti-platelet therapy they had, and practical guidelines were communicated to the attending physician. More investigations with angiography or MRA were performed in cases of worsened symptoms and/or recurrent stenosis of more than 50% or thrombosis on duplex scan.
Continuous variables were expressed by mean and standard deviations, whereas categorical data were presented in frequencies and percentages. Non-parametric Mann-Whitney tests were performed, when appropriate, to compare mean scores across the groups, whereas 2 or Fisher exact tests were used to compare frequencies.
Survival data were updated for March 2006 following contact with the patients or their referring physicians. The following variable was considered to be a potential prognostic factor for survival: stent vs non-stent. Survival was calculated only on technically successful SA, using the Kaplan-Meier product limit method from the date of the operation, and included the operative primary, primaryassisted, and secondary patency, as well as related or unrelated death. Comparisons were made using the log-rank test. P values of 0.05 or less were considered to be statistically significant. This statistical analysis was performed using the SPSS V13.0 software package (SPSS Inc, Chicago, Ill).
RESULTS
A total of 53 patients (54 limbs) were consecutively treated with SA for disabling claudication (n ϭ 19) or critical limb ischemia (n ϭ 34) from September 2003 to October 2005. Thirty-four limbs (64%) had a stent placed (group 2), and 19 (35.8 %) did not (group 1). The two groups were comparable with respect to age, the presence of diabetes, American Society of Anesthetists (ASA) grade, combined procedures, presentation (Rutherford classification 14 ), and history of previous lower extremity bypass (Table I ). The mean length of the lesions treated was 20.11 cm (range, 5-35 cm); 15.8 cm in group 1 (range, 5-35 cm) and 22.5 cm (range, 5-30 cm) in group 2. There was no statistically significant difference in lesion length, TransAtlantic Inter-Society Consensus (TASC) classification, and the number of run-off vessels between the two groups.
The procedure was technically successful in 94.5% of cases. In the three other cases, failure was attributed to the inability to reenter the true lumen because of heavy calcification (n ϭ 2) and the line suture from a previous bypass (n ϭ 1). These patients underwent a surgical bypass in one case, major amputation in another. The third patient with disabling claudication received only medical treatment and underwent no further medical intervention.
Combined procedures were required in the treatment of 59.2% (n ϭ 32) of limbs (68.2% in group 1 and 55.8% in group 2) to improve inflow (n ϭ 23, 42.5%) or outflow (n ϭ 9, 16.6%). In CLI, these procedures were performed in 22 patients, including open femoral bifurcation endarterectomy (n ϭ 13), iliac angioplasty with or without stenting (n ϭ 4), and tibial artery angioplasty or recanalization (n ϭ 5). In claudicants, 10 patients had combined procedures with open femoral bifurcation endarterectomy (n ϭ 6) or iliac artery angioplasty with or without stenting (n ϭ 4) as inflow procedures. There was no difference in the adjunctive procedures between the two groups (P ϭ .1). The Viabahn stent graft was used in all cases. The mean diameter of the stent graft used was 6 mm (range, 5-6 mm). The mean number of stent grafts deployed in the recanalized artery was 1.6 Ϯ 0.65 (range, 1-3) with a mean total length of 21.25 Ϯ 10.26 cm.
There were two peri-or postprocedural complications (5.8%) in group 2 (one groin hematoma and one groin infection) and two (10.5%) in group 1 (one distal embolus treated with thrombolysis and thromboaspiration and one retroperitoneal hematoma). At 30 days, we had two deaths in each group. All the patients concerned were Ͼ80 years old, in ASA grade IV, with critical limb ischemia, and were unfit for infrainguinal bypass. The two patients in group 1 died on days 5 and 6, respectively from congestive heart failure and unexplained sudden death. In group 2, one patient died of myocardial infarction on day 1 and the second of general condition impairment owing to metastatic cancer on day 7.
The mean follow up was 16.89 months (range, 1-35 months). At 1 year, the primary, primary-assisted, and secondary patency rates were 78.9 % in group 1 and, respectively, 61.8%, 70.6%, and 88.2% in group 2 ( Figs  1-3 ). There was no significant difference in primary patency (P ϭ .49), in primary-assisted patency (P ϭ .78), or in secondary patency (P ϭ .22) between the two groups.
Secondary intervention was performed in 70% of patients (n ϭ 7) in group 2 and 50% of patients (n ϭ 1) in group 1 after occlusion of the treated arterial segment. Three of the seven patients who had occluded the stents Group 1  19  9  5  2  Group 2  34  18  12  6 36,00 24,00 12,00 0,00 developed an acute ischemia. In group 1, the unique patient who occluded the treated artery had only mild claudication.
Numbers at risk_____________________________________________
The one-year limb salvage rate for the stent vs the non-stent group was 94.1% vs 100% (P ϭ .7; Fig 4) . The two cases of major (below-the-knee) amputation in the stent group were in patients initially treated for CLI at 1 and 3 months because of thrombosis in the first case and, in the second case, infection and major tissue loss despite the good permeability of the revascularization.
DISCUSSION
The standard treatment for long femoro-popliteal occlusions remains bypass surgery. Since the subintimal angioplasty technique was first developed in 1989, 15 it has become possible to treat long chronic occlusions of the SFA as well as the tibial arteries. This technique offers some advantages over infrainguinal bypass and conventional angioplasty and, for some investigators, is a real alternative. 9, 16 Since 2003, we have modified our policy regarding the management of occlusive disease with femoro-popliteal occlusions. In order to avoid bypass and preserve the saphenous veins in young patients with disabling claudication and suitable lesions for SA, in primary intention we attempt subintimal recanalization. The less invasive techniques using intra-or extraluminal recanalization are also restricted to patients with CLI and severe comorbidities or to those who have unsuitable veins for bypass. The short-term safety and feasibility of SA have been well established, with high technical success rates (80%-90%) and a high rate of limb salvage. 2, 6, 17, 18 Unfortunately, the patency rate remains controversial, and, in recent studies, the primary patency rates range between 22% and 74% at 12 months. [2] [3] [4] [5] 19, 20 In the initial technique described by Bolia, 1 there was no need to use a stent, except in cases of perforation or intimal flaps at the entry site. In our establishment, we have modified the Bolia technique 12 with a view to improving patency. We combine the standard SA technique with stenting along the whole length of the recanalized artery in order to contain the atherosclerotic plaque and intimal flap. The stent is used only if the reentry site does not extend beyond the knee joint, which avoids interference with later bypass surgery in case of occlusion, and also reduces the risk of stent fracture.
During the same period, we also treated long SFA occlusions using the standard subintimal angioplasty technique. The choice between the two SA techniques, with or without stenting, depended on the surgeon's preference and lesion extension in relation to the knee joint.
There is only one study 9 that investigates the role of stenting in improving the outcome of subintimal angioplasty by comparing two groups, with and without stent. In this report, Schmieder et al 9 showed that a selective stent placed after SA resulted in similar patency to primary SA without stents. Two other large studies 10, 11 assessed the impact of routine stenting on patency after SA and reported a relatively favorable outcome. Treiman et al, 10 in a study of 29 patients, stented along the entire length of the dissection, found good short and intermediate-term patency, but poor long-term patency, probably explained by myo-intimal hyperplasia. Kim et al 11 combined primary stenting of the proximal segment with SA for long occlusions, and obtained a primary patency and limb salvage rate at 12 months of 52% and 83%, respectively.
In our study, primary patency and primary-assisted patency at 12 months in the stent group were, respectively, 61.8% and 70.6%. The two groups were totally comparable with regard to the number of run-off vessels and occlusion length. While the other studies used only self-expanding nitinol stents, [9] [10] [11] in our series, we used only the Viabahn stent graft, and this for three main reasons. First, good results have been achieved with covered stents in the treatment of occlusive SFA lesions. 21, 22 Second, the restenosis rate was low compared with non-covered stents, 22, 23 and, finally, there is the possibility of having 10-cm-to 15-cmlong stents, thus avoiding placement of multiple stents in the SFA and reducing the fracture rate.
One of the advantages of subintimal angioplasty is the maintenance of and possible opening up of collaterals, 24 which probably explains the high rate of limb salvage with this technique on the one hand and the possible reocclusion of the artery without recurrence of symptoms on the other. Some investigators suggest that stents may jeopardize the collateral vessels and thus have a detrimental effect on patency, especially when stenting concerns the entire length of the recanalized artery. Treiman et al 10 reported a long-term patency rate that was inferior to that of other studies that did not use routine stenting and consequently do not recommend stenting the entire length of the dissection. In our experience, we found no difference in patency between patients treated with or without covered stents, so we do not believe that coverage of the major collateral vessels affects patency. Schmieder et al 9 noted a trend for SA patients receiving stents to require more open bypass surgery than those without stents.
The occlusion interval generally reported in the literature is the first 6 months, except for Treiman et al, 10 who found that patency declined considerably after 24 months. In our study, as in Yilmaz's study, 25 most thromboses occurred within the first 6 months with the same kinetics in both groups. This suggests that a more aggressive surveillance protocol every 3 months in the first year is necessary in order to detect restenosis early and avoid thrombosis, regardless of whether there is a stent or not.
The mortality rate in our series was relatively high compared with the literature. London et al 7 presented a series of SA on 200 femoro-popliteal artery occlusions with a 30-day mortality rate of 1.5%. Hynes et al 26 reported a 15-year experience of CLI management with SA; the 30-day mortality rate was 4%. The relatively high mortality rate in our series can be explained mainly by the fact that all our patients were ASA grade IV with critical limb ischemia, and had combined procedures due to extensive lesions. In retrospect, we now believe that surgical abstention or immediate major amputation should be offered to these patients.
There are several limitations of our study. First, it is a retrospective review, which contributed to incomplete data collection. Second, as the addition of stent is nonrandomized, but depended on the surgeon's preference and the extension of the femoro-popliteal occlusion, this might create bias for the clinical outcome. Our results should thus be regarded with caution. Third, the relatively small number of patients in each group and the short follow up do not permit a further stratification of results. Finally, different anti-platelet regimens had been used, which creates another bias.
This retrospective clinical study revealed no difference in the patency of the SA, either with or without stents. We are, nevertheless, convinced that the results of SA plus stenting can be improved by treating the origin of the SFA properly, beyond the proximal occlusion, and by closer clinical and duplex-scan monitoring, combined with a more aggressive policy in the treatment of restenosis.
CONCLUSION
Combining subintimal angioplasty and stent grafts of the entire recanalized artery offers both high technical success and a satisfactory patency rate. The limb salvage rate is not affected by the addition of the stent and remains high, as with the Bolia technique. 1 Close monitoring in the first year and the early treatment of restenosis will probably improve the outcome of the procedure. Our encouraging results allow us to propose this therapeutic option in the treatment of CLI in elderly patients, and as a primary therapy with a view to postponing surgical bypass in patients with intermittent claudication. 
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